Simplify Life with Omnipod® 5

 

Omnipod 5 with a dashboard view on phone screen Omnipod 5 with a dashboard view on phone screen
Pod shown without the necessary adhesive. Screen for illustrative purposes only.

No multiple daily injections or finger prick testing‡. Omnipod 5 proactively helps to correct highs and protect from lows1,2 –simplify your diabetes management.

How it works

Every five minutes the glucose Sensor reports glucose levels to the Pod. SmartAdjust™ technology within the Pod automatically adjusts your insulin.

  • When glucose levels are dropping, insulin delivery automatically decreases or pauses.
  • When glucose levels are rising, insulin delivery automatically increases.
 

 

Get to know the Omnipod 5 System

Patient in room with Pod on their left arm Patient in room with Pod on their left arm

The Pod

Tubeless, wearable, and waterproof†, each Pod sits comfortably on the body for up to 3 days (72 hours), automatically adjusting insulin delivery thanks to its built-in SmartAdjust™ technology.

Learn more about Pod therapy

 

A person holding a controller while using the Omnipod 5 app A person holding a controller while using the Omnipod 5 app

The Controller

Take charge of your diabetes with the handheld Omnipod 5 Controller, which connects seamlessly to your Pod via Bluetooth® for discreet, wireless control.

 

Sensors, G7 and Freestyle libre 2 plus Sensors, G7 and Freestyle libre 2 plus
Automated mode requires compatible sensor. Compatible sensors are sold and prescribed separately. Sensor availability may vary per country or region.

The Sensor

Your choice of compatible Sensor continuously sends glucose values to the Pod, giving you real-time readings§ without the hassle of finger pricks‡. The Pod and Sensor need to be in ‘line of sight’ to stay in Automated Mode. Placing them on the same side of the body allows for best communication between the devices.

Connect to Omnipod Discover™

Omnipod Discover is the diabetes data management system that connects to Omnipod 5. By connecting your Omnipod 5 account with Omnipod Discover you have the ability to share your data with your healthcare professional allowing you to:

  • Review your personalised diabetes insights including insulin delivery insights, trends and patterns 
  • Share data with your Healthcare professional and/or diabetes clinic 
  • Receive weekly detailed reports from Discover providing overall insulin usage and readings from your glucose monitoring sensor

3 simple parts. One continuous loop of communication.

Pod sensors Pod sensors
Pod and Sensors shown without necessary adhesive. Screens for illustrative purposes only.

When paired with a compatible Continuous Glucose Monitor (CGM) sensor, Omnipod 5 can give constant and automatic insulin delivery to keep you in range, day and night2-3. Omnipod 5 is compatible with Dexcom G7, and FreeStyle Libre 2 Plus Sensor..

Here’s what our Podders have to say about Omnipod®:

Omnipod 5 has allowed me to get a good night sleep. That's the first time I can say that in a long time.

Alvin
Podder since 2017

It helps me feel like a normal kid, just with a little bit of help.

Romey T.
Sponsored Omnipod® User
& Podder since 2019

I don’t have to spend as much time thinking about diabetes.

Clare F.
Podder® since 2013

Speak with your healthcare provider to find out more!

Looking for Omnipod resources?

To learn more about Omnipod 5, check out our library of resources.

‡Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

†The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.

1. The Omnipod 5 System was named 2023 Patient Choice Award Winner for preferred pump in the United States; Source: Seagrove Patient Perspectives Survey Report (413 Total Responses, 260 T1D, 153 T2D 245 pumpers, 98 MDI, 70 non-MDI). Seagrove Partners, LLC Patient Perspectives Report, December 2023. Insulet data on file.

2. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Average time with low blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 2.9% vs. 1.3%; 2.2% vs. 1.8%. Study funded by Insulet.

3. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.41% vs. 2.13%. Study funded by Insulet.

‡Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

†The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.

1. The Omnipod 5 System was named 2023 Patient Choice Award Winner for preferred pump in the United States; Source: Seagrove Patient Perspectives Survey Report (413 Total Responses, 260 T1D, 153 T2D 245 pumpers, 98 MDI, 70 non-MDI). Seagrove Partners, LLC Patient Perspectives Report, December 2023. Insulet data on file.

2. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Average time with low blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 2.9% vs. 1.3%; 2.2% vs. 1.8%. Study funded by Insulet.

3. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.41% vs. 2.13%. Study funded by Insulet.

Risk Statement

The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older.

The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U- 100 insulins: NovoLog®, Humalog®, and Admelog®.

The Omnipod 5 ACE Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 ACE Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values.

The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.

WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit https://www.omnipod.com/en-gb/safety for additional important safety information.

WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.